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Cardiovascular disease is a complex disorder involving multiple pathophysiological processes, several of which involve activation
of toll-like receptors (TLRs) of the innate immune system. As sentinels of innate immunity TLRs are nonclonally germline-
encoded molecular pattern recognition receptors that recognize exogenous as well as tissue-derived molecular dangers signals
promoting inflammation. In addition to their expression in immune cells, TLRs are found in other tissues and cell types including
cardiomyocytes, endothelial and vascular smooth muscle cells. TLRs are diﬀerentially regulated in various cell types by several
cardiovascular risk factors such as hypercholesterolemia, hyperlipidemia, and hyperglycemia and may represent a key mechanism
linking chronic inflammation, cardiovascular disease progression, and activation of the immune system. Modulation of TLR
signaling by specific TLR agonists or antagonists, alone or in combination, may be a useful therapeutic approach to treat various
cardiovascular inflammatory conditions such as atherosclerosis, peripheral arterial disease, secondarymicrovascular complications
of diabetes, autoimmune disease, and ischemia reperfusion injury. In this paper we discuss recent developments and current
evidence for the role of TLR in cardiovascular disease as well as the therapeutic potential of various compounds on inhibition of
TLR-mediated inflammatory responses.
1. Introduction: Innate Immunity and
Toll-Like Receptors (TLRs)
Historically the immune system has been divided into
the innate and the adaptive immune system. Neutrophils,
eosinophils, basophils, mast cells, monocytes, macrophages,
dendritic cells (DCs), NK cells, NK-T cells, γδ T cells, and
B-1 cells are considered to be cellular members of the innate
immune system which can be activated by signaling through
TLR. In addition, endothelial cells may form part of this
system since they also possess antigen-presenting capabilities
and therefore immune regulation properties apart from their
function as a barrier between tissue and blood [1].
A year after the discovery of the role of drosophila Toll
protein in the host defense against fungal infection [2], a
mammalian homologue was identified, referred to as TLR4
[3]. Since then, 13 members of the TLR family have been
identified in mammals, ten in humans, and twelve in mice.
Mice do not express TLR10 but do express TLR11, TLR12,
and TLR13 [4]. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11
are displayed on the cell surface while TLR3, TLR7, TLR8,
and TLR9 are localized intracellularly. TLRs are distributed
and diﬀerentially expressed in several cell types and tissues.
They are present on polymorphonuclear cells, macrophages,
mast cells, DC, NK cells, T cells, and B cells. Interestingly,
TLR expression has also been detected on cardiac, epithelial,
endothelial, and vascular smooth muscle cells. Moreover,
mesenchymal and parenchymal cells of diﬀerent organs and
tissue such as kidney, heart, lung, liver, skin, brain and
intestine express TLR, but their functional role and relevance
is not yet fully understood [5].
The molecular weight of TLR ranges between 90 and
115 kDa. The extracellular region of Toll contains leucine-
rich repeat (LRR) motifs whereas the cytoplasmic domain
has similarities with that of the mammalian Interleukin-
1 receptor (IL-1R) family and is designated as Toll/IL-1R
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(TIR) homology domain, containing around 200 amino
acids.Within this domain, the regions of homology comprise
three conserved boxes, which are crucial for signaling.
After ligand binding, TLRs dimerize and undergo the
conformational change required for recruitment of down-
stream signaling molecules. In general, these include the
adaptor molecule, myeloid diﬀerentiation primary-response
protein 88 (MyD88), TIR-domain-containing adaptor pro-
tein (TIRAP; also known as MyD88-adaptor-like protein
or Mal), IL-1R-associated kinases (IRAKs), transforming
growth factor-β- (TGF-β-) activated kinase (TAK1), TAK1-
binding protein 1 (TAB1), TAB2, and tumor-necrosis factor
(TNF) receptor-associated factor 6 (TRAF6) [6, 7]. The TLR
family signaling pathway is highly homologous to that of the
IL-1R family and represents the core pathway of all TLR,
except for TLR3. Studies in 2001 revealed the existence of a
MyD88-independent pathway since stimulation of MyD88-
deficient DC with LPS still induced their maturation [8].
Therefore, exposure to LPS induces TLR4-signaling via a
MyD88-dependent as well as MyD88-independent pathway,
which subsequently activates IRF3 [9]. Up to now, TLR3-
signaling is considered to be MyD88 independent [7].
Importantly, there seems to be a diﬀerence between TLR
signaling induced by endogenous versus exogenous ligands
which may in part be due to diﬀerential TLR signaling
complex formation [10].
2. Toll-Like Receptors in Autoimmune and
Cardiovascular Disease
The concept that innate immune signaling can be triggered
not only by external pathogens but also by endogenous
molecules released in response to tissue injury was first
proposed almost two decades ago by Matzinger [11]. Subse-
quently, it was shown that antigen-presenting cells, namely,
DC, can be activated by a variety of endogenous stimuli
[12]. Since then further advances in this area have been
surprisingly slow and only recently their emerging potential
role in cardiovascular disease has become to be recognized as
summarized in Figure 1 [13].
In this context, several endogenously derived molecules
released from necrotic cells, so-called damage-associated
molecular patterns (DAMPs) or alarmins, have been iden-
tified, which lead to “sterile inflammation” via activation
of TLR. In addition, other molecules released from dying
cells, for example, proteinases also lead to the generation of
extracellular DAMP by degradation of components of the
extracellular matrix or glycocalyx. DAMPs now encompass
a wide range of molecules including heat shock proteins,
high-mobility group box 1 (HMGB1) protein, a chromatin-
binding nuclear protein, ATP, uric acid, heparan sulfate (HS),
hyaluronan, and others [14, 15]. These molecules have been
shown to bind to diﬀerent TLRs or other molecular pattern
recognition receptors (PRRs) expressed on various cell types
and trigger the release of proinflammatory mediators.
2.1. Atherosclerosis: Interaction of Risk Factors and TLR.
Excessive accumulation of lipids in macrophages resulting in
foam cell formation is a hallmark of atherosclerosis. TLR4
has been shown to contribute to early-stage intimal foam cell
accumulation at lesion-prone aortic sites in ApoE KO mice,
as does TLR2 to a lesser extent [16]. Intimal smooth muscle
cells surround and penetrate early lesions, where TLR4 sig-
naling, enhanced by hypercholesterolemia, promotes lesion
progression by stimulation of acyl-coenzyme A: cholesterol
acyltransferase-1 mRNA expression, cytoplasmic cholesterol
ester accumulation, and monocyte chemoattractant protein-
1 (MCP-1) mRNA and protein expression in a TLR4-
dependent manner. Other TLRs also appear to be involved.
Lipid accumulation in macrophages is closely linked to the
PAT family of proteins (named after perilipin, adipophilin,
and TIP47 (tail-interacting protein of 47 kDa). TLR9-
mediated signaling stimulates perilipin 3 expression and
macrophage accumulation of lipids, especially triglycerides.
Oligodeoxynucleotide (ODN) 1826, an agonist ligand of
TLR9, significantly enhanced perilipin 3 expression in
RAW264.7 cells via upregulation of IL-1α and IFNβ, whilst
chloroquine, a TLR9 inhibitor, virtually completely abol-
ished ODN1826-induced perilipin 3 expression. Inhibitors
of c-jun NH2-terminal kinase and PI3-kinase suppressed the
level of perilipin 3 mRNA induced by ODN1826 [17].
Not all eﬀects of TLR activation, however, may be
detrimental. Soluble forms of human TLR2 (sTLR2) have
been shown to be released by monocytes, and depletion of
sTLR2 resulted in an exaggerated inflammatory response
[18]. Patients with postmyocardial infarction and heart
failure have also been shown to have markedly decreased
sTLR2 compared to controls [19].
Recent studies indicate that neointima formation in a
perivascular collar-induced injury model is reduced by sys-
temic administration of the dsRNA analog poly(I:C) (a TLR3
agonist) in a TLR3-dependent manner. Furthermore, genetic
deletion of TLR3 markedly enhanced the development of
elastic lamina damage after collar-induced injury and accel-
erated the onset of atherosclerosis in hypercholesterolemic
ApoE knockout mice [20]. Collectively, these data suggest
a protective role for TLR3 signaling in the vessel wall.
Taken together, current data indicates that the contribution
of TLR signaling to the progression of the atherosclerotic
process may depend, at least in part, on a balance between
detrimental and protective TLR-mediated mechanisms. This
in turn may depend not only on changes in the relative
expression of appropriate receptors on relevant cell types but
also on the relative availability of endogenous ligands.
2.2. Diabetes, Insulin Resistance, and Other Cardiovascular
Risk Factor Interactions with TLR. Other cardiovascular risk
factors, notably diabetes, obesity, and insulin resistance,
are also associated with a low-grade inflammatory state
that reflects activation of innate immunity associated with
metabolic, environmental, and genetic factors. Evidence
suggests, for example, that resistin, originally described
as an adipose tissue-specific hormone, is involved in
pathologic processes leading to CVD including inflam-
mation, endothelial dysfunction, thrombosis, angiogenesis,
and smooth muscle cell dysfunction. Recent data indicates
that a key mechanism underlying its detrimental eﬀects
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Figure 1: Summary of current data implicating TLR signaling in various cardiovascular disease processes (figure modified from [13]). BMP:
bone morphogenetic protein; Runx2: Runt related transcription factor 2; FGF: fibroblast growth factor; PDGFA: platelet derived growth
factor A; MMP: matrix metalloproteinase; ROS: reactive oxygen species; VSMC: vascular smooth muscle cells; ECM: extracellular matrix;
LDL: low density lipoprotein; CXCL1: chemokine (C-X-C motif) ligand 1; MIP: macrophage-inflammatory protein; ICAM: intracellular
adhesion molecule; iNOS: inducible nitric oxide synthase.
in these processes is that TLR4 serves as a receptor for
the proinflammatory eﬀects of resistin in human cells [21,
22]. This may partly explain the multifunctional role of
resistin in chronic inflammation, atherosclerosis, and insulin
resistance. Similarly, nutritional fatty acids, whose circulating
levels are often increased in obesity, activate TLR4 signaling
in adipocytes and macrophages and the capacity of dietary
fatty acids to induce inflammatory signaling in adipose cells
or tissue and macrophages is blunted in the absence of
TLR4.
Other studies suggest an association between the
Asp299Gly polymorphism of the TLR4 gene and early
onset of diabetic retinopathy in type 2 diabetic patients
[23]. TLR2 and TLR4 expressions as well as signaling have
also been shown to be enhanced in monocytes of patients
with Type 1 diabetes with microvascular complications
[24]. This may contribute to the accentuated proinflam-
matory state and complications of T1DM. Underlying
molecular mechanisms linking these observations appear to
involve complex-formation between advanced glycation end
product-modified oxidized low-density lipoprotein (AGE-
LDL), the receptor for advanced glycation end products
(RAGE), and the scavenger receptor CD36 [25]. Subsequent
activation of downstream signaling pathways induced by
binding of this complex to TLR4 results in activation of
p38-α, JNK, and ERK1 kinases and AP1, Elk1, and NFκB
transcription factors leading to increased production of
TNFα and proinflammatory cytokines. These mechanisms
may partly underlie the increased risk of atherosclerosis
observed in diabetics. Two common polymorphisms in
TLR4, D299G and T399I, were shown in vitro to reduce
the response of TLR4 to LPS but had no eﬀect on
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Figure 2: Cardiac I/R injury activates multiple inflammatory pathways such as complement, coagulation, and/or innate immune cells by
binding of danger signals via expressed TLR. LMW-DXS: low molecular weight dextran sulfate, HMGB1: high-mobility group protein box
1, HSP: heat shock proteins.
the AGE-LDL-complex signaling. This supports data from
other studies suggesting that TLR activation by DAMP may
activate alternative downstream proinflammatory pathways
to those induced by pathogen-associated ligands.
3. Toll-Like Receptors in Cardiac I/R Injury
3.1. Toll-Like Receptors as Sentinels of Innate Immunity
in Cardiac I/R Injury. There is an increasing number of
studies demonstrating a major role of TLR in several animal
models of ischemia reperfusion (I/R) injury. Cardiac I/R
injury has a significant clinical relevance as, for example,
in heart transplantation (HTx), myocardial infarction (MI),
or coronary artery bypass graft surgery. Tissue damage
and inflammation occurs after coronary artery occlusion
(ischemia) when reperfusion occurs (restoration of blood
flow). A hallmark of I/R injury is a strong activation of
the innate immune system, that is, activation of com-
plement and coagulation, recruitment of innate immune
cells, cytokine release, formation of reactive oxygen species
(ROS), mitochrondrial dysfunction, as well as apoptosis and
cell necrosis (Figure 2). Studies with TLR deficient mice
have demonstrated a crucial role of TLR2 and TLR4 in
I/R injury-mediated inflammatory responses in the heart
[26, 27]. Kaczorowski et al. showed in a murine cardiac
transplantation model that serum levels of TNF-α, IL-1β,
IL-6, troponin I, and MCP-1 were dramatically reduced in
mice deficient in TLR4 signaling. Furthermore, these mice
had reduced intragraft mRNA levels of TNF-α, IL-1β, IL-
6, EGR-1, ICAM-1, and iNOS [26]. In a mouse model of
myocardial infarction, TLR4 deficiency resulted in less tissue
damage and cardioprotection [28]. A cardioprotective eﬀect
has also been observed for mice deficient for TLR2, for
example, by a reduced infiltration of neutrophils into the
tissue [27]. The exact role of TLR2 however is somewhat
controversial since, in other studies, TLR2 agonist ligands
were reported to induce cardioprotection, mediated via a
TLR2/PI3K/Akt-dependent mechanism [29]. The reason for
these conflicting reports is currently unclear but may reflect
diﬀerences between chronic and acute models of I/R injury.
3.2. Interplay of TLR with Other Members of Innate Immunity
in Cardiac I/R Injury. I/R injury leads to the activation of
multiple inflammatory pathways. Furthermore, there is an
active interplay between pathways such as TLR and com-
plement. The release of the nonmuscle myosin from dying
cells is recognized by naturally occurring IgM antibodies,
resulting in complement activation and tissue damage [30].
Interestingly, the anaphylatoxin and complement cleavage
product C5a has been shown to negatively regulate produc-
tion of IL-12 family members such as IL-12, IL-23, and IL-
27 in inflammatory macrophages [31]. Furthermore, mice
deficient in the membrane complement regulator CD55
(DAF) have elevated levels of TNF-α, IL-1β, and IL-6 in
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Table 1: Non selective-TLR antagonists in cardiovascular disease.
Compound
In vitro (TLR inhibition)
In vivo (cardiac I/R injury, HTx)
TLR/cells TLR agonists
LMW-DXS
TLR2 and TLR4/human MoDC [33]
TLR2/human NK cells [50]
TLR2: LTA, Pam3CSK4
TLR4: LPS, HS
MI/pig [48]
HTx/rat [49]
Xeno HTx/hamster-to-rat [92]
IVIg
TLR4/human MoDC [64]
TLR9/human B cells [66]
TLR4: LPS
TLR9: CpG Oligos
HTx/human [63]
C1-INH
TLR4/murine macrophage cell line
RAW264.7 [70]
TLR4: LPS
MI/pig [68]
MI/cat [69]
HTx/human [63]
ATIII TLR4/human monocytic cell line THP1 [75] TLR4: LPS HTx/mice [76]
α1AT TLR4/human monocytes [79] TLR4: LPS MI/mice [80]
rHDL TLR4/human monocytes [87] TLR4: LPS MI/rat [86]
Statins
TLR4/human monocytes [89]
TLR4/human MoDC [90]
TLR4: LPS
MI/human [93]
HTx/human [88]
HS: heparan sulfate; HTx: heart transplantation; MI: myocardial infarction; MoDC: monocyte-derived dendritic cells: LTA: lipoteichoic acid; LPS:
lipopolysaccharide.
response to TLR agonists, whereas the levels of IL-12p40 are
slightly decreased [32].
Interestingly, the endogenous TLR4 ligand heparan
sulfate (HS) has been shown to induce the production
of complement proteins C1q or C3 by human monocyte-
derived DC (MoDC) [33] whereas exogenous LPS reduced
secretion of C1q [34]. In addition, exogenous C1q seems to
potentiate the LPS-induced secretion of IL-12p70 by human
MoDC in vitro [35]. Another study has reported decreased
levels of IL-12p70 secretion by DC after LPS-challenge in
patients deficient for C1q [36].
Another important characteristic of I/R injury is the
very low oxygen level during ischemia. Hypoxia induces
the expression of the transcription factor hypoxia-inducible
factor-1α (HIF-1α) which has been described as a key
regulator of a broad range of cellular and systemic responses
to hypoxic conditions. Recent studies suggest a cross-talk
betweenHIF-1α and TLR. It has been shown that stimulation
of human MoDC with LPS under hypoxic conditions
resulted in a significantly higher expression of the costimula-
tory molecules CD80 and CD86 [37]. The same synergistic
eﬀect was observed for murine bone-marrow-derived DC
[38]. In addition, HIF-1α regulates the expression of VEGF
and endothelin-1 (ET-1), a potent vasoactive peptide known
to be involved in cardiac I/R injury [39]. Stimulation of
macrophages as well as MoDCwith TLR agonists induces the
secretion of VEGF and ET-1 [40, 41].
3.3. Strategies to Inhibit TLR Activation in Cardiac I/R
Injury. Specific inhibition of TLR2 with a monoclonal
antibody has been demonstrated to attenuate myocardial
I/R injury in mice [42]. Similarly, eritoran, a synthetic
lipid-A analogue which inhibits TLR4 signaling, was ben-
eficial in a mouse model of myocardial infarction [43].
It should be noted however that I/R injury is a mul-
tifactorial injury involving many diﬀerent inflammatory
pathways and to target one single pathway might not be
suﬃcient. Hence, combination therapies may show greater
eﬃcacy.
To date several compounds have been described, many
of them already routinely used in the clinics for other
indications, which have been shown to inhibit TLR signaling
in vitro and to possess therapeutic potential in animal models
of MI or HTx. Therefore, we will discuss in the following
paragraphs compounds which have shown to have anti-
inflammatory activity on various pathways of cardiac I/R
injury such as the coagulation or complement cascade,
TLR signaling, leukocyte recruitment, NK cell activation,
maturation of DC, and others (summarized in Table 1).
3.3.1. Low Molecular Weight Dextran Sulfate (LMW-DXS).
Low molecular weight dextran sulfate (LMW-DXS, MW:
5000 Dalton) has various anti-inflammatory properties.
Inhibition of all three activation pathways of complement
is mediated by binding to factor H [44] and enhance-
ment of the activity of C1-INH [45]. Furthermore, LMW-
DXS inhibits coagulation by enhancing the anticoagulatory
activity of antithrombin III (ATIII) and C1-INH against
activated factor XI [46]. Interestingly, LMW-DXS interferes
with platelet adhesion [47] and has beneficial eﬀects in
diﬀerent animal models of cardiac I/R injury. In a pig
model of acute myocardial I/R injury, LMW-DXS signif-
icantly reduced infarct size [48] and facilitated anti-CD4
mAb-induced long-term cardiac allograft survival in rats
despite prolonged cold graft ischemia [49]. LMW-DXS also
inhibited TLR2- and TLR4-mediated maturation of human
MoDC and prevented the upregulation of costimulatory
molecules including CD40, CD80, and CD86 on MoDC in a
dose-dependent manner. Secretion of the proinflammatory
cytokines TNF-α, IL-6, and IL-1β was also significantly
reduced. As a functional consequence of these eﬀects,
antigen-presentation to T cells was prevented. TLR-induced
signal transduction, phosphorylation of IκB-α, as well as
activation of the downstream proinflammatory transcription
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factor NFκB were also inhibited by LMW-DXS [33]. An asso-
ciated in vitro study showed similar eﬀects of LMW-DXS on
TLR2-mediated activation of human NK cells. Phenotypic
activation was significantly inhibited by LMW-DXS as shown
by a reduced upregulation of CD25, CD56, CD69, as well
as NKp44. Furthermore, release of IFNγ was significantly
reduced and degranulation of NK cells was attenuated as
evaluated by the upregulation of CD107a [50]. LMW-DXS
also interferes with activation of MoDC by the endogenous
TLR4 ligand, heparan sulfate proteoglycan (HSPG). This is
rapidly released from the vascular endothelial surface under
conditions of inflammation and tissue damage [51–53] by
proteolytic cleavage of the protein core or by endoglycolytic
cleavage of the HS chains [53, 54]. In the plasma of vascular
surgery patients, elevated levels of syndecan-1 and HS were
found as early as 15 minutes after reperfusion [55]. Free
HS has been considered to act as DAMP, since it induces
maturation of macrophages and DC via TLR4 [56–58].
Overall, LMW-DXS is well tolerated in humans and
induces an increase in the anti-inflammatory hepatocyte
growth factor (HGF) in plasma [59]. In addition it not
only acts as a complement and coagulation inhibitor but
also modulates innate immune cells as, for example, shown
by inhibition of NK cell activation. Moreover, the crosstalk
between innate and adaptive immunity is prevented by
inhibition of TLR-mediated maturation of DC. Hence,
LMW-DXS and similarly acting, nontoxic inhibitors of
complement, coagulation, and TLR activation may be
of therapeutic interest for the prevention of cardiac I/R
injury.
3.3.2. Intravenous Immunoglobulins (IVIgs). IVIg products
are derived from pooled human plasma of thousands of
donors and have been used for decades as replacement
therapy for patients with hypogammaglobulinemia, such
as X-linked agammaglobulinemias or common variable
immunodeficiencies. In addition, anti-inflammatory therapy
with high-doses of IVIg is used clinically in a variety of acute
or chronic autoimmune disease as, for example, Idiopathic
Thrombocytopenic Purpura (ITP), Kawasaki Disease, or
Guillain Barre´ Syndrome. Several anti-inflammatory prop-
erties of IVIg have been described for IVIg preparations
including complement inhibition, anticytokine antibodies,
inhibition of leukocyte rolling, induction of T regulatory
cells, and others as published and reviewed by others [60–
62]. Importantly, IVIg has successfully been used in the clinic
as a combination therapy for a patient undergoing cardiac
transplantation [63]. A few reports have demonstrated an
inhibitory eﬀect of IVIg on TLR-mediated activation of
immune cells in vitro. One study investigated the eﬀect of
IVIg on diﬀerentiation of monocytes into MoDC as well as
the eﬀect of IVIg on TLR4-mediated maturation of MoDC.
Pretreatment of MoDC with IVIg followed by stimulation
with LPS resulted in reduced upregulation of the costim-
ulatory molecules CD40, CD80, and CD86. Furthermore,
upregulation of MHC class II, the key molecule for antigen-
presentation, was prevented by IVIg. Interestingly, LPS-
induced secretion of IL-12p70 was inhibited whereas the
anti-inflammatory cytokine IL-10 was significantly upreg-
ulated. No inhibition was observed for the secretion of
the proinflammatory cytokine TNF-α. Importantly, DC-
mediated T cell proliferation analyzed in mixed leukocyte
reaction (MLR) with allogeneic T cells was reduced by
IVIg [64]. A recent study has further investigated the eﬀect
of IVIg on the diﬀerentiation of CD14 positive human
monocytes into MoDC. Ballow and Allen demonstrated
that IVIg primarily modulates the diﬀerentiation of “TLR-
primed” monocytes before subsequent diﬀerentiation into
MoDC by IL-4 andGM-CSF. Interestingly, priming with poly
I/C (TLR3 agonist) in combination with IVIg did not result
in an increase of CD83 expression, as observed for the other
used TLR agonists [65]. Controversial results were observed
regarding DC-induced proliferation of allogeneic T-cell. This
study demonstrated an increase of T cell proliferation by
IVIg-diﬀerentiated DC [65] whereas Bayry et al. have shown
a decrease of T cell proliferation [64].
The eﬀect of TLR9 stimulation by CpG oligonucleotides
on B cells of SLE patients as well as healthy donors has been
investigated. Coincubation of B cells with IVIg (10mg/ml)
and CpG oligos resulted in a decreased secretion of IL-6 as
well as IL-10. IVIg had a similar inhibitory eﬀect on the
activation of human B cells isolated from SLE patients and
healthy controls [66].
It would be of interest if IVIg also interferes with cell
activation induced by DAMP. As shown by Bayry et al., IVIg
preparations contain specific LPS antibodies [64]. Therefore,
some of the observed inhibitory eﬀects might be explained
by binding and neutralization of the exogenous agonist used,
namely LPS.
3.3.3. C1-Esterase Inhibitor (C1-INH). C1-INH has been
reported to have various anti-inflammatory properties. Ini-
tially C1-INH has been characterized as a potent inhibitor
of the classical pathway of complement activation. Follow-
up studies provided evidence for inhibition of the mannan-
binding lectin as well as the alternative pathway of comple-
ment activation. Protease inhibition has been reported for
kallikrein, factor XI, factor XII, plasmin, tissue plasminogen
activator (tPA), and thrombin. Furthermore, binding to
neutrophils, macrophages, and endothelial cells (ECs) has
also been shown [67]. In the clinic, C1-INH is commonly
used to treat patients with C1-INH deficiencies who suﬀer
from Hereditary Angioedemia (HAE).
In vivo, treatment with C1-INH has been demonstrated
to be beneficial in diﬀerent models of cardiac I/R injury
[68, 69]. In addition, C1-INH has successfully been used
as a combined therapy for a patient undergoing cardiac
transplantation [63]. Only one study has investigated the
eﬀect of C1-INH on TLR4-mediated activation of a murine
macrophage cell line. Inhibition of LPS-mediated activation
of murine macrophages seems to be mediated by binding
and neutralization of LPS by C1-INH [70]. N-glycosylation
of the protein seems to be important for binding of LPS
[71]. Interestingly, C1-INH also binds to graft EC, while
still maintaining its function as complement inhibitor as
shown in a model of ex vivo perfused porcine livers [72] and
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could therefore potentially be used as an additive to organ
preservation solutions in order to protect the graft from I/R
injury.
3.3.4. Antithrombin III (ATIII). ATIII is a major inhibitor of
the coagulation system and acts as a potent inactivator of
thrombin and factor Xa. Clinically, ATIII concentrates are
used to treat inherited ATIII deficiencies [73]. Apart from
coagulation inhibition, ATIII has been shown to interfere
with leukocyte adhesion in vitro and in vivo [74]. ATIII also
possesses eﬀective anti-inflammatory properties. Mansell
et al. have demonstrated an inhibitory eﬀect of ATIII on
TLR4-mediated nuclear translocation of the proinflamma-
tory transcription factor NFκB in the human monocytic
cell line THP1 [75]. There are no other reports so far
showing an inhibitory eﬀect of ATIII on other TLR agonist-
induced activation of immune cells. Interestingly, in a mouse
model of cardiac transplantation, high doses of ATIII have
been shown to induce long-term graft survival. Induction
of regulatory cells by ATIII has been suggested but not
demonstrated by the authors [76].
3.3.5. Alpha-1 Antitrypsin (α1AT). α1AT is routinely used in
the clinic to treat patients with α1AT deficiency and lung
emphysema. α1AT is a potent inhibitor of the neutrophil
enzyme elastase. An imbalance between α1AT and elastase
increases the risk of emphysema [77]. In a mouse model of
silica-induced inflammation, influx of granulocytes in the
lungs was significant inhibited by α1AT. Interestingly α1AT
inhibited activation of the proinflammatory transcription
factor NFκB in lungs [78]. An in vitro study investigated the
eﬀect of α1AT on the TLR4-mediated activation of human
primarymonocytes. Only long-term (18 hours) cell exposure
to a1AT inhibited LPS-induced upregulation of the proin-
flammatory mediators TNF-α, IL-1β, and IL-8. In contrast,
short-term exposure to α1AT/LPS increased the expression
of TNF-α, IL-1β, and IL-8. Furthermore, long-term exposure
of monocytes to α1AT/LPS decreased the surface expression
of CD14 and TLR4 [79]. Recently, a study performed by
Toldo et al. demonstrated a beneficial eﬀect of α1AT in
a mouse model of myocardial infarction. Infarct size was
significant reduced in the group treated with α1AT compared
with the control treated with albumin. In addition, α1AT
treatment significantly reduced cytokine/chemokine tissue
levels of IL-6, IL-10, IL-17, TNF-α, and MCP-1 [80]. Further
investigations are necessary to determine the molecular
mechanism of α1AT mediated inhibition of TLR-induced
activation of cells. Interestingly, it has been speculated by
Johnson et al. that elastase released by activated neutrophils
might be a major in vivo mechanism by which HS is cleaved
from the surface of vascular EC and subsequently induces
inflammation via TLR4 [81].
3.3.6. Reconstituted High-Density Lipoprotein (rHDL). A
beneficial eﬀect of treatment with reconstituted High-
Density Lipoprotein (rHDL), containing apolipoprotein A-
I and phosphatidylcholine (PC), has been described in
multiple diseases including arteriosclerosis, MI, stroke, and
endotoxemia. rHDL has been reported to inhibit upreg-
ulation of inflammatory adhesion molecules like ICAM-1
(CD54), VCAM-1 (CD106) and E-selectin (CD62E), on EC
[82] as well as reduce thrombin-induced tissue-factor (TF)
expression [83]. Furthermore, a recent study in humans
has shown that rHDL reduces plasma levels of TNF-α and
expression of CD11b on monocytes [84]. Protection against
cardiac I/R injury has been demonstrated in ex vivo perfused
rat hearts in association with a reduced cardiac content of
TNF-α and enhanced secretion of prostaglandin [85]. In vivo,
rHDL has been shown to prevent left ventricle remodeling
and improve heart function after MI. Nitric oxide levels
in plasma were significantly reduced in the rHDL-treated
group, whereas no decrease in IL-6 levels was observed
[86]. An eﬀect of rHDL on TLR4-mediated inflammation
has been demonstrated in gram-negative sepsis via binding
and neutralizing LPS and reduction of CD14 expression on
monocytes [87]. Overall, rHDL attenuates the proinflamma-
tory eﬀects of many mediators of innate immunity.
3.3.7. Statins. HMG-CoA reductase inhibitors, namely,
statins, have been reported to have broad anti-inflammatory
biological properties. In a single center study of HTx patients,
statins are even thought to have immunosuppressive prop-
erties. Lipid lowering therapy was strongly associated with
an improvement in one-year survival of the patients whereas
no diﬀerence was reported regarding graft rejection [88].
In addition, statins have been demonstrated to inhibit the
upregulation of CD86 as well as MHC class II on MoDC and
as consequence, allogeneic T cell activation and proliferation
was prevented.
Interestingly, pretreatment of primary human mono-
cytes with atorvastatin and simvastatin significantly inhibited
the secretion of IL-6, IL-12, and TNF-α. In addition, LPS-
induced upregulation of the costimulatory molecule CD80
was significantly inhibited by both statins. Furthermore,
atorvastatin as well as simvastatin induced a decrease in
TLR4 expression at the protein as well as the mRNA level
in human monocytes [89]. In addition, statins have been
demonstrated to inhibit the upregulation of CD86 as well as
MHC class II on MoDC and as a consequence, allogeneic T
cell activation and proliferation were prevented [90].
4. Discussion
Accumulating evidence indicates that TLR may play impor-
tant roles in the pathogenesis of atherosclerosis, microvascu-
lar complication of diabetes, viral myocarditis, dilated car-
diomyopathy, cardiac allograft rejection, and sepsis-induced
left ventricular dysfunction. Moreover, heart failure of
diverse etiology is also now recognized to have an important
immune component, with TLR signaling influencing the
process of cardiac remodeling and prognosis. In cardiac I/R
injury, studies with TLR2 and TLR4 deficient mice have
suggested a crucial involvement of these receptors in the early
process of inflammation. In addition, blockade with TLR2
or TLR4 antagonists has been shown to have a beneficial
eﬀect in MI [42, 43]. Several danger molecules or DAMP
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Table 2: Selective-TLR antagonists in cardiovascular disease.
Compound Target Indication Drug class Clinical phase Company
OPN-305 TLR2
Inflammation,
autoimmunity, I/R injury
Antibody Preclinical Opsona Therapeutics
Eritoran TLR4
Sepsis
I/R injury (preclinical)
Synthetic
lipopolysacharide
Phase III Eisai Pharmaceuticals
TAK-242 TLR4 Sepsis, inflammation Small-molecule inhibitor Discontinued in phase III Takeda
NI-0101 TLR4
Inflammation, autoimmunity,
CVD, I/R injury, and so forth
Antibody Preclinical Novimmune
IMO-3100
TLR7 and
TLR9
SLE, RA, MS, atherosclerosis DNA-based compound Preclinical Idera Pharmaceuticals
CVD: cardiovascular disease; MS: multiple sclerosis; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; I/R: ischaemia reperfusion.
identified in vitro are suggested to be the ligands of TLR and
therefore the initiators of sterile inflammation, but overall,
there is still no direct evidence in vivo that these molecules
are the drivers of the inflammatory process. Cardiac I/R
is a multifactorial injury resulting in the activation of
several proinflammatory pathways such as the complement
or coagulation system (Figure 2). Inhibition of complement
has been demonstrated to be cardioprotective in I/R injury
but had no eﬀect on patients treated with fibrinolysis for
acute MI [91]. There are several compounds described,
most of them already routinely used in the clinic to treat
patients, for example, C1-INH or IVIg, which inhibit various
proinflammatory pathways including TLR. Antagonism of
these pattern recognition receptors might contribute to the
observed therapeutic eﬀect of these substances shown in
various animal models of cardiac I/R injury. Most of the
“nonselective” TLR antagonists summarized in Table 1 seem
to mainly target TLR4, but in almost all studies, only LPS
was used as activating agent. Whether these compounds
might also inhibit TLR signaling induced by other TLR
ligands, exogenous as well as endogenous, remains to be
investigated. Despite the large amount of evidence, based
largely on animal studies, that TLRs are involved in a
wide range of pathological cardiovascular processes, clinical
translation of therapeutic targeting of TLR in CVD in
man is still in the early stages. Two TLR4 antagonists,
E5564 (Eritoran) by Eisai, Inc., and TAK-242 by Takeda
Pharmaceutical Company, have been used in phase III
clinical trials for the management of severe sepsis where
the drugs ware largely well tolerated. For cardiovascular
diseases, Eritoran also showed some preclinical benefits
and attenuated myocardial I/R injury by inhibiting TLR4.
Currently, there are no additionally published clinical trial
data looking at TLR antagonists as a therapeutic for CVD
(Table 2).
This slow progress may have several causes. In most
cases, it is unclear as to how and to what extent various
TLR receptors and signaling pathways are altered in diﬀerent
CVDs. In virtually all cases, how the complete family of
TLR is altered in diﬀerent disease states is unknown. This
may have various consequences particularly if activation
of specific TLR has protective eﬀects. Eﬀective therapeutic
intervention may require antagonist blockade of detrimental
receptors and simultaneous agonist treatment of beneficial
TLR receptor responses. Another major drawback may be
the limitations of currently used animal models to mimic
the clinical entity being targeted. In most cases, CVD occurs
against a background of one or more other pathological
processes such as hyperlipidemia, atherosclerosis, and hyper-
glycemia each of which may diﬀerentially modify the TLR
receptor and signaling profile in any given tissue or cell
type. Rarely are experimental therapeutic profiles performed
in atherosclerotic prone diabetic mice when evaluating, for
example, peripheral arterial disease. Until the profiles of TLR
changes are fully understood, it is unlikely that monotherapy
targeting a single TLR entity will prove to be eﬀective in
treating CVD.
Thus, more experiments are warranted to study the
detailed profile of TLR changes in CVD and the diﬀerential
or additive eﬀects of one or more risk factors that are known
to influence disease progression or outcome.
Abbreviations
CVD : Cardiovascular Disease
DC : Dendritic cell
DAMP : damage-associated-molecular-pattern
HTx : Heart Transplantation
I/R injury : Ischemia/Reperfusion injury
IVIg : Intravenous Immunoglobulins
LMW-DXS : Low molecular weight dextran sulfate
MI : Myocardial infarction
MoDC : monocyte-derived dendritic cells
TLR : Toll-like receptors.
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